Literature DB >> 28289072

Down-regulation of miR-15a/b accelerates fibrotic remodelling in the Type 2 diabetic human and mouse heart.

Shruti Rawal1, Pujika Emani Munasinghe1, Prashanth Thevkar Nagesh2, Jason Kar Sheng Lew1, Gregory T Jones3, Michael J A Williams4, Philip Davis5, Dick Bunton5, Ivor F Galvin5, Patrick Manning4, Regis R Lamberts1, Rajesh Katare6.   

Abstract

Aim: Myocardial fibrosis is a well-established cause of increased myocardial stiffness and subsequent diastolic dysfunction in the diabetic heart. The molecular regulators that drive the process of fibrotic events in the diabetic heart are still unknown. We determined the role of the microRNA (miR)-15 family in fibrotic remodelling of the diabetic heart.Methods and results: Right atrial appendage (RAA) and left ventricular (LV) biopsy tissues collected from diabetic and non-diabetic (ND) patients undergoing coronary artery bypass graft surgery showed significant down-regulation of miR-15a and -15b. This was associated with marked up-regulation of pro-fibrotic transforming growth factor-β receptor-1 (TGFβR1) and connective tissue growth factor (CTGF), direct targets for miR-15a/b and pro-senescence p53 protein. Interestingly, down-regulation of miR-15a/b preceded the development of diastolic dysfunction and fibrosis in Type 2 diabetic mouse heart. Therapeutic restoration of miR-15a and -15b in HL-1 cardiomyocytes reduced the activation of pro-fibrotic TGFβR1 and CTGF, and the pro-senescence p53 protein expression, confirming a causal regulation of these fibrotic and senescence mediators by miR-15a/b. Moreover, conditioned medium (CM) collected from cardiomyocytes treated with miR-15a/b markedly diminished the differentiation of diabetic human cardiac fibroblasts.
Conclusion: Our results provide first evidence that early down-regulation of miR-15a/b activates fibrotic signalling in diabetic heart, and hence could be a potential target for the treatment/prevention of diabetes-induced fibrotic remodelling of the heart.
© 2017 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28289072     DOI: 10.1042/CS20160916

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  33 in total

1.  Molecular Pathogenesis of Chlamydia Disease Complications: Epithelial-Mesenchymal Transition and Fibrosis.

Authors:  Joseph U Igietseme; Yusuf Omosun; Tamas Nagy; Olga Stuchlik; Matthew S Reed; Qing He; James Partin; Kahaliah Joseph; Debra Ellerson; Zenas George; Jason Goldstein; Francis O Eko; Claudiu Bandea; Jan Pohl; Carolyn M Black
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

Review 2.  LncRNAs and miRs as epigenetic signatures in diabetic cardiac fibrosis: new advances and perspectives.

Authors:  Hui Tao; Zheng-Yu Song; Xuan-Sheng Ding; Jing-Jing Yang; Kai-Hu Shi; Jun Li
Journal:  Endocrine       Date:  2018-07-27       Impact factor: 3.633

3.  YAP1/Twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF.

Authors:  Yingzhun Chen; Xiaoguang Zhao; Jian Sun; Wei Su; Lu Zhang; Yingnan Li; Yingqi Liu; Lijia Zhang; Yanjie Lu; Hongli Shan; Haihai Liang
Journal:  Cell Death Differ       Date:  2019-01-15       Impact factor: 15.828

4.  Cardiac mesenchymal cells from diabetic mice are ineffective for cell therapy-mediated myocardial repair.

Authors:  Parul Mehra; Yiru Guo; Yibing Nong; Pawel Lorkiewicz; Marjan Nasr; Qianhong Li; Senthilkumar Muthusamy; James A Bradley; Aruni Bhatnagar; Marcin Wysoczynski; Roberto Bolli; Bradford G Hill
Journal:  Basic Res Cardiol       Date:  2018-10-23       Impact factor: 17.165

Review 5.  Diabetic fibrosis.

Authors:  Izabela Tuleta; Nikolaos G Frangogiannis
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-12-28       Impact factor: 5.187

Review 6.  Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides.

Authors:  Nilanjan Ghosh; Rajesh Katare
Journal:  Cardiovasc Diabetol       Date:  2018-03-22       Impact factor: 9.951

7.  Progressive Decrease in Coronary Vascular Function Associated With Type 2 Diabetic Heart Disease.

Authors:  Rajesh Katare; James T Pearson; Jason Kar-Sheng Lew; Melanie Wei; Hirotsugu Tsuchimouchi; Cheng-Kun Du; Dong-Yun Zhan; Keiji Umetani; Mikiyasu Shirai; Daryl O Schwenke
Journal:  Front Physiol       Date:  2018-06-06       Impact factor: 4.566

8.  Overexpression of p53 due to excess protein O-GlcNAcylation is associated with coronary microvascular disease in type 2 diabetes.

Authors:  Rui Si; Qian Zhang; Atsumi Tsuji-Hosokawa; Makiko Watanabe; Conor Willson; Ning Lai; Jian Wang; Anzhi Dai; Brian T Scott; Wolfgang H Dillmann; Jason X-J Yuan; Ayako Makino
Journal:  Cardiovasc Res       Date:  2020-05-01       Impact factor: 10.787

Review 9.  Epigenetics, microRNA and Metabolic Syndrome: A Comprehensive Review.

Authors:  Farha Ramzan; Mark H Vickers; Richard F Mithen
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

Review 10.  Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities.

Authors:  Izabela Tuleta; Nikolaos G Frangogiannis
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.